Immunic (NASDAQ:IMUX) Releases Earnings Results, Misses Expectations By $0.37 EPS

Immunic (NASDAQ:IMUX) posted its earnings results on Wednesday. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.37), FiscalAI reports.

Immunic Stock Performance

IMUX traded down $0.57 during mid-day trading on Friday, reaching $12.08. 161,098 shares of the stock were exchanged, compared to its average volume of 336,241. The stock has a market capitalization of $164.53 million, a PE ratio of -2.16 and a beta of 1.20. The company has a 50 day moving average price of $11.43 and a two-hundred day moving average price of $8.61. Immunic has a 1 year low of $5.06 and a 1 year high of $15.10.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Guggenheim assumed coverage on shares of Immunic in a research report on Tuesday, March 24th. They set a “buy” rating and a $70.00 price target on the stock. Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Sunday, April 19th. HC Wainwright restated a “buy” rating and issued a $22.00 price target (up from $5.00) on shares of Immunic in a research note on Thursday, April 30th. Lifesci Capital upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, May 4th. Finally, D. Boral Capital downgraded shares of Immunic from a “buy” rating to a “hold” rating in a research report on Wednesday, April 15th. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Immunic has a consensus rating of “Buy” and an average target price of $50.86.

Hedge Funds Weigh In On Immunic

A number of hedge funds and other institutional investors have recently made changes to their positions in IMUX. Qube Research & Technologies Ltd purchased a new stake in Immunic during the third quarter valued at about $29,000. Two Sigma Investments LP purchased a new stake in Immunic during the third quarter valued at about $52,000. HB Wealth Management LLC purchased a new stake in Immunic during the third quarter valued at about $81,000. Seven Fleet Capital Management LP purchased a new stake in Immunic during the fourth quarter valued at about $83,000. Finally, Virtu Financial LLC purchased a new stake in Immunic during the third quarter valued at about $99,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.